NCT01007123

Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation

A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of Elobixibat in Patients With Chronic Idiopathic Constipation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 190 (actual)
• Sponsor: Albireo · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with chronic idiopathic constipation.

Conditions

• Constipation
• Chronic Constipation

Interventions

Type	Name	Description
DRUG	A3309	A3309 in three different dosage levels or placebo once daily for the duration of the study

Timeline

• Start date: 2009-11-01
• Primary completion: 2010-10-01
• Completion: 2010-10-01
• First posted: 2009-11-03
• Last updated: 2017-03-22
• Results posted: 2017-03-22

Locations

44 sites across 1 country: United States